Bortenat 3.5mg Injection

Product Description

1. Technical Specifications

2. Product Description

Bortenat 3.5 mg Injection contains Bortezomib, a reversible proteasome inhibitor that disrupts protein degradation within cells, leading to apoptosis (programmed cell death) in cancer cells.

It is mainly used in the management of multiple myeloma and mantle cell lymphoma. The injection can be administered by IV push (35 seconds) or subcutaneous injection, as directed by a healthcare professional.

3. Product Highlights

4. Therapeutic Uses

• Multiple Myeloma frontline and relapsed/refractory cases

• Mantle Cell Lymphoma in patients who have received at least one prior therapy

• Investigated in other cancers (off-label) under physician supervision

5. Side Effects

Common:

• Fatigue, weakness

• Nausea, vomiting, diarrhea, constipation

• Loss of appetite, weight loss

• Peripheral neuropathy (numbness, tingling in hands/feet)

• Thrombocytopenia, neutropenia, anemia

• Fever, infections

Serious / Severe:

• Severe neuropathy (pain, loss of sensation)

• Heart problems (congestive heart failure, arrhythmias)

• Lung complications (acute respiratory distress, pneumonitis)

• Liver toxicity (increased enzymes, hepatitis)

• Tumor lysis syndrome (rare but serious)

6. Precautions

• Bone Marrow Suppression: Monitor complete blood counts before each dose.

• Neuropathy: Dose modification or discontinuation required in severe peripheral neuropathy.

• Cardiac Function: Use with caution in patients with heart disease or risk of fluid overload.

• Kidney & Liver Impairment: Dose adjustments required.

• Pregnancy & Breastfeeding: Contraindicated potential teratogenic effects; effective contraception needed.

• Drug Interactions: Caution with strong CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin, phenytoin) as they may affect bortezomib metabolism.